Vertex Pharmaceuticals IncorporatedVRTXNASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank93
3Y CAGR+15.8%
5Y CAGR+16.1%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+15.8%/yr
vs +15.7%/yr prior
5Y CAGR
+16.1%/yr
Consistent
Acceleration
+0.1pp
Accelerating
Percentile
P93
Near historical high
vs 5Y Ago
2.1x
Strong expansion
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $5.51B | -43.4% |
| 2024 | $9.72B | +103.6% |
| 2023 | $4.78B | +34.8% |
| 2022 | $3.54B | -8.9% |
| 2021 | $3.89B | +48.9% |
| 2020 | $2.61B | +8.3% |
| 2019 | $2.41B | +22.2% |
| 2018 | $1.97B | +8.4% |
| 2017 | $1.82B | +23.0% |
| 2016 | $1.48B | - |